<DOC>
	<DOCNO>NCT00815763</DOCNO>
	<brief_summary>The purpose phase 3 study validate efficacy safety ginsenoside-Rd acute ischemic stroke .</brief_summary>
	<brief_title>Efficacy Safety Ginsenoside-Rd Acute Ischemic Stroke</brief_title>
	<detailed_description>A phase â…¢ randomize , double-blind , placebo-controlled , multicenter study conduct examine efficacy safety ginsenoside-Rd patient acute ischemic stroke . Stroke patient randomize equally receive 14-day infusion placebo ginsenoside-Rd 20mg . Primary end point NIHSS score 15 day . Secondary end point NIHSS score Barthel index 8 day , Barthel index modify Rankin scale 15 day 90 day . The safety end point include serious nonserious adverse event , laboratory value vital sign . Analysis intention treat .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>18 75 year first episode onset admission within 72 hour NIHSS scores:5~22 intracranial pathology ( e.g. , tumor , infection ) neurologic psychiatric disease coexist condition limit life expectancy significant drug alcohol misuse highgrade carotid artery stenosis surgery plan pregnant nursing participate clinical trial investigational drug device within past 3 month unlikely available followup</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>randomize trial</keyword>
	<keyword>ischemic stroke</keyword>
	<keyword>Ginsenoside-Rd</keyword>
</DOC>